Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers

Neuropsychopharmacology

Volumn 40, Issue 11, 2015, Pages 2489-2498

  Haney, Margaret ^a   Ramesh, Divya ^a,b   Glass, Andrew ^a   Pavlicova, Martina ^a,c   Bedi, Gillinder ^a   Cooper, Ziva D ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; RIBOFLAVIN; CANNABIS; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; COGNITION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FATIGUE; FEMALE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STOMACH DISEASE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; AFFECT; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; DRUG THERAPY; EATING; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PSYCHOLOGY; RANDOMIZATION; URINE; YOUNG ADULT;

ADULT; AFFECT; BLOOD PRESSURE; CANNABIS; DOUBLE-BLIND METHOD; EATING; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RANDOM ALLOCATION; RIBOFLAVIN; SELF ADMINISTRATION; YOUNG ADULT;

EID: 84941316835     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.108     Document Type: Article

References (56)

1. Anton RF (2008). Naltrexone for the management of alcohol dependence. N Engl J Med 359: 715-721.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003-2017.
3. Balter R, Cooper ZD, Haney M (2014). Novel pharmacologic approaches to treating cannabis use disorder (invited review). Curr Addict Rep 1: 137-143.
4. Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD et al (2010). Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 212: 675-686.
5. Braida D, Pozzi M, Cavallini R, Sala M (2001). Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104: 923-926.
6. Buckner JD, Zvolensky MJ, Ecker AH (2013). Cannabis use during a voluntary quit attempt: an analysis from ecological momentary assessment. Drug Alcohol Depend 132: 610-616.
7. Budney AJ, Moore BA, Rocha HL, Higgins ST (2006). Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74: 307-316.
8. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007). Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22-29.
9. Cerdá M, Wall M, Keyes KM, Galea S, Hasin D (2012). Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend 120: 22-27.
10. Chait LD, Pierri J (1989). Some physical characteristics of NIDA marijuana cigarettes. Addict Behav 14: 61-67.
11. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebocontrolled trial. Arch Gen Psychiatry 63: 210-218.
12. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL (2008). The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96: 1-15.
13. Cooper ZD, Haney M (2008). Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 13: 188-195.
14. Cooper ZD, Haney M (2010). Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology 211: 141-148.
15. Evans SM, Troisi JR 2nd, Griffiths RR (1994). Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 271: 683-694.
16. Foltin RW, Brady JV, Fischman MW, Emurian CS, Dominitz J (1987). Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend 20: 87-93.
17. Greenwald MK, Stitzer ML (2000). Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59: 261-275.
18. Haney M (2007). Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32: 1391-1403.
19. Haney M (2009). Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14: 9-21.
20. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD et al (2013a). Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 73: 242-248.
21. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW (2013b). Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38: 1557-1565.
22. Haney M, Bisaga A, Foltin RW (2003). Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166: 77-85.
23. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C et al (2004). Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158-170.
24. Haney M, Spealman R (2008). Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199: 403-419.
25. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141: 395-404.
26. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW (2005). Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181: 237-243.
27. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G et al (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 194: 505-515.
28. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322-328.
29. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165: 1442-1448.
30. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173: 186-194.
31. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM (2007). Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 32: 1220-1236.
32. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL (2011). Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377: 1506-1513.
33. Lee MW, Fujioka K (2009). Naltrexone for the treatment of obesity: review and update. Exp Opin Pharmacother 10: 1841-1845.
34. Levin FR, Mariani JJ, Brooks DJ, Cheng W, Nunes EV (2011). Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116: 142-150.
35. Lozano BE, Stephens RS, Roffman RA (2006). Abstinence and moderate use goals in the treatment of marijuana dependence. Addiction 101: 1589-1597.
36. Marijuana Treatment Project Research Group (2004). Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72: 455-466.
37. Mason BJ, Goodman AM, Dixon RM, Abdel Hameed MH, Hulot T, Wesnes K et al (2002). A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27: 596-606.
38. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350.
39. O'Malley SS, Jaffe AJ, Chang G, Schottenfield RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
40. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craivng and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamopituitary-adrenocortical axis. Psychopharmacology 160: 19-29.
41. Oncken C, Van Kirk J, Kranzler HR (2001). Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154: 397-402.
42. Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP (2000). Improving naltrexone response. J Addict Dis 19: 71-83.
43. Rios C, Gomes I, Devi LA (2006). Mu opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
44. Robledo P, Berrendero F, Ozaita A, Maldonado R (2008). Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 13: 213-224.
45. Scavone JL, Sterling RC, Van Bockstaele EJ (2013). Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248: 637-654.
46. Solinas M, Goldberg SR (2005). Involvement of mu-, delta-and kappa-opoioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology 179: 804-812.
47. Stoops WW, Rush CR (2013). Agonist replacement for stimulant dependence: a review of clinical research. Curr Pharm Des 19: 7026-7035.
48. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (2012). Drug Abuse Warning Network (DAWN), 2008: National Estimates of Drug-Related Emergency Department VisitsHHS Publication No. (SMA) 11-4618. SAMHSA: Rockville, MD.
49. Substance Abuse and Mental Health Services Administration (SAMHSA) (2013). Results from the 2012 National Survey on Drug Use and Health: summary of national findingsNSDUH Series H-46, HHS Publication No. (SMA) 13-4795. SAMHSA
50. Rockville, MD. Taylor D (2009). Withdrawal of rimonabant-walking the tightrope of 21st centry pharmaceutical regulation? (Opinion). Curr Drug Safety 4: 2-4.
51. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D (2013). The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128: 64-70.
52. Verebey K, Volavka J, Mule SJ et al (1976). Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20: 315-328.
53. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
54. Wachtel SR, de Wit H (2000). Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 59: 251-260.
55. Wakley AA, Craft RM (2011). THC-methadone and THCnaltrexone interactions on discrimination, antinociception, and locomotion in rats. Behav Pharmacol 22: 489-497.
56. Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R et al (2014). Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse 40: 16-22.